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BACKGROUND: Breast cancer becomes lethal when visceral metastases develop. At this stage, anti-cancer treatments aim at relieving
symptoms and delaying death without resulting in additional toxicity. On the basis of their differential anti-oxidant defence level,
tumour cells can be made more sensitive to chemotherapy than non-tumour cells when membrane lipids are enriched with
docosahexaenoic acid (DHA), a peroxidisable and oxidative-stress-inducing lipid of marine origin.
METHODS: This open-label single-arm phase II study evaluated the safety and efficacy (response rate), as primary end points, of the
addition of 1.8g DHA daily to an anthracycline-based chemotherapy (FEC) regimen in breast cancer patients (n¼25) with rapidly
progressing visceral metastases. The secondary end points were time to progression (TTP) and overall survival (OS).
RESULTS: The objective response rate was 44%. With a mean follow-up time of 31 months (range 2–96 months), the median TTP was
6 months. Median OS was 22 months and reached 34 months in the sub-population of patients (n¼12) with the highest plasma
DHA incorporation. The most common grade 3 or 4 toxicity was neutropaenia (80%).
CONCLUSION: DHA during chemotherapy was devoid of adverse side effects and can improve the outcome of chemotherapy when
highly incorporated. DHA has a potential to specifically chemosensitise tumours.
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Breast cancer is the most frequent cancer in women, with an
incidence of 41 million new cases in the world in 2002, with
360000 cases in Europe (http://www-dep.iarc.fr/). A significant
proportion of patients die because of the development of
metastases. At this stage, survival length and quality of life depend
on disease sensitivity to anti-cancer treatments. Despite the advent
of innovative approaches, current treatments still rely heavily on
conventional chemotherapy. Efficacy of chemotherapy is usually
dose dependent. Dose is limited by side effects as a consequence of
toxicity to non-tumour tissues, which results from the poor
selectivity of anti-cancer drugs for tumours. Thus, any approach
aimed at increasing tumour sensitivity to chemotherapy while not
affecting non-tumour tissues has a potential to improve metastatic
breast cancer prognosis and clinical outcome.
Several research groups, including ours, have shown that
docosahexaenoic acid (DHA), a lipid of marine algal origin mainly
provided by diet, has, experimentally, the ability to increase the
efficacy of anti-cancer agents. This highly unsaturated fatty acid
incorporates into cell membrane phospholipids, particularly in fast
growing or proliferating cells such as tumour cells or tumour
tissues, as tumour fatty acid composition is influenced by dietary
lipids (Chajes et al, 1995). Using cultured breast cancer cell lines, it
was reported that pre-enrichment of these cells with DHA
enhanced their sensitivity to a variety of anti-cancer classes of
drugs (Begin et al, 1986; Menendez et al, 2005; Wang et al, 2007)
and more specifically to anthracyclines, an oxidative stress-
inducing anti-cancer drug with a quinone structure (Germain
et al, 1998; Mahe ´o et al, 2005). Furthermore, a prolonged (several
weeks) supplementation with DHA (fish oil or algae-derived
DHA), initiated before and continued during chemotherapy,
consistently increased the sensitivity of autochthonous mammary
tumours to anti-cancer drugs (Shao et al, 1997; Hardman et al,
2001; Colas et al, 2005, 2006). Similar results have been observed
with radiation therapy (Colas et al, 2004). This indicates
that dietary DHA can make mammary tumours more sensitive to
anti-cancer agents. DHA-induced tumour chemosensitisation
or radiosensitisation was abolished by the concomitant addition
of a-tocopherol, an anti-oxidant molecule (Colas et al, 2004, 2005)
in a dose-dependent manner (Colas et al, 2006). With six double
bonds, DHA is one of the most peroxidisable fatty acids and the
increased sensitivity of tumour cells to chemotherapy may result in
part from peroxidation of membrane-enriched DHA, as a
consequence of the oxidative stress induced by anti-cancer drugs
(Mahe ´o et al, 2005).
Several findings suggest that this increased sensitivity applies
preferentially to aggressive tumour cells. We reported that cell
defences against oxidative stress differ among cell lines, and found
a deficiency in glutathion peroxidase induction by reactive oxygen
species (ROS) in MDA-MB-231, a breast cancer cell line with
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sparticularly aggressive features, whereas MCF-7, a breast cancer
cell line with less-advanced features of tumour progression,
retained the complete set of anti-oxidant defences (Vibet et al,
2008). This indicates that the handling of ROS is altered along with
tumour progression. As DHA incorporates into cell membranes,
this differential handling of ROS may account for the selectivity of
DHA-induced tissue sensitisation by anti-cancer agents in tumour
tissues compared with non-tumour tissues. Along this line, the
lack of additional toxicity in non-tumour tissues has been
consistently documented under conditions in which tumour tissue
DHA was sensitised to chemotherapy (Hardman et al, 1999; Kato
et al, 2002; Germain et al, 2003; Xue et al, 2007) or radiation
therapy (Wen et al, 2003) in rodents.
On the basis of these results, we conducted a pilot phase II
clinical trial in metastatic breast cancer patients to investigate
the efficacy and safety of adding DHA to an ROS-generating
chemotherapy regimen, that is an anthracycline-based regimen
(FEC). We found that the combination was safe while retaining
significant anti-tumour activity in the sub-population of patients
with high plasma DHA incorporation, suggesting that DHA has a
potential to specifically chemosensitise tumours.
MATERIALS AND METHODS
Study design
This study aimed at investigating the efficacy and safety of the oral
administration of DHA in breast cancer patients receiving an
anthracycline-based chemotherapy as first-line therapy for metas-
tases. It was designed as a prospective open-labelled phase II trial,
performed in one single institution (University Hospital
Bretonneau in Tours, France). Patients presenting with inclusion
criteria were sequentially enrolled. The primary end points were
response rate and safety profile. Secondary end points were time to
progression (TTP) and overall survival (OS). The protocol was
approved by the Tours University Hospital Ethic Committee in
accordance with French law, and all patients signed an informed
consent before inclusion.
Patient eligibility
Breast cancer patients with visceral metastases that were not
amenable to hormonal therapy or alternative treatment and
without earlier chemotherapy for metastases were eligible. Earlier
adjuvant or neo-adjuvant therapy, with or without anthracyclines
(maximum cumulative dose of p250mgm
 2 for doxorubicin,
400mgm
 2 for epirubicin and 72mgm
 2 for mitoxanthrone), was
allowed if completed at least 6 months before the study, as was
adjuvant locoregional radiation therapy. Other criteria included
age above 25 and below 75 years, Eastern Cooperative Oncology
Group performance status (Oken et al, 1982) p2 and life
expectancy of at least 12 weeks. At least one bi-dimensionally
measurable visceral lesion not located in fields irradiated in the
earlier 4 months was required. Adequate bone marrow, renal and
hepatic functions were required for study entry. Cardiac eligibility
requirement was a left ventricular ejection fraction (LVEF) X55%.
Patients were ineligible if they had a history of any other cancer
(with the exception of non-melanoma skin cancer or cervical
carcinoma in situ), bilateral (without other metastatic location) or
inflammatory breast cancer. Patients included in any experimental
study within the last 30 days were also excluded.
Treatments
To achieve a sufficient incorporation of DHA into tissue cell
membrane phospholipids, an amount of 1.8g/day of DHA was
chosen on the basis of earlier studies carried out in healthy
individuals and recently reviewed (Arterburn et al, 2006). DHA
was provided as 0.5g capsules of DHASCO containing DHA-
enriched triglyceride oil of algal origin (44% DHA providing 0.2-g
DHA). DHASCO capsules were kindly supplied by Martek
Biosciences Corp. (Columbia, MD, USA). Patients received nine
capsules of DHASCO daily (representing 200mg  9¼1.800mg
DHA/day), as three capsules at each meal. DHA was administered
from inclusion before initiation of chemotherapy (a 7–10-day
loading period) and then for the 5 months of chemotherapy.
Patients were explicitly asked to avoid any intake of anti-oxidants.
They kept a daily record of their DHASCO intake, which was
controlled every 3 weeks and further monitored by a capsule count
at the end of the study. Compliance below 80% of the planned dose
would have led to withdrawal of the patient from the study.
FEC 75 chemotherapy, the standard of first-line chemotherapy in a
metastatic setting at the time of accrual (Bonneterre et al, 2004),
consisted of an intravenous infusion of cyclophosphamide
(500mgm
 2), an i.v. bolus of fluorouracil (500mgm
 2), followed
by an i.v. infusion of epirubicin (75mgm
 2). This treatment was
administered on day 1 every 3 weeks. DHA was suspended on the
day of chemotherapy administration. Duration was at least six
cycles, except in the case of disease progression, unacceptable
toxicity, patient refusal or any medical condition requiring study
arrest. In case of a positive response after six cycles, treatment
could be extended to nine cycles. Adjuvant or metastatic hormonal
therapy was discontinued at study entry.
Patient monitoring, safety assessment and toxicity
management
Complete clinical examination, biochemical analysis, electro-
cardiogram, cardiac sonography and pulmonary testing (spirometry,
gas diffusion) were performed at baseline. Clinical exami-
nation and a biochemical analysis were repeated at day 1 of each
cycle. Adverse events were graded according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC, version 2.0,
http://www.recist.com). Sonographic assessment of cardiac
function was additionally performed by a single team of
sonographists at the end of the study or when cardiac toxicity
was suspected.
Treatment adaptation involved FEC regimen and not DHA.
Dexamethasone and ondansetron were authorised anti-emetic
drugs. Prophylactic granulocyte-colony-stimulating factor was
authorised when required. Should a second episode of neutropaenia
occur despite granulocyte-colony-stimulating factor, the dose of
epirubicin would have to be reduced to 60mgm
 2. Dose delay to a
maximum of 2 weeks was allowed in patients with an absolute
neutrophil count of o1.5 10
9/l
 1 and/or a platelet count of
o100 10
9/
 1 at day 22 (second cycle). Grades 3–4 non-
haematological toxicity resistant to symptomatic treatment
required epirubicin dose reduction to 60mg/m
2. If it was persistent
despite dose reduction, patients were withdrawn from the study.
Cessation of chemotherapy was required when signs of congestive
heart failure occurred on the basis of functional criteria for
cardiotoxicity or LVEF p45%.
Tumour response and survival assessments
Assessement of tumour response through clinical and radiological
evaluations was performed every two cycles, and compared with
baseline. Imaging included computed tomography scans or
abdominal sonography, bone scan, standard X-rays or magnetic
resonance imaging, where appropriate. Response rate was
evaluated according to the Response Evaluation Criteria in Solid
Tumors (RECIST version 1.0) guidelines (http://www.recist.com).
Response was defined as complete response (CR), partial response
(PR), stable disease (SD) or progressive disease (PD). The objective
response rate (ORR) was defined as CR plus PR, divided by the
number of patients. Clinical benefit was defined as the sum of CR,
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sPR and SD, divided by the number of patients. Metastases-free
interval was defined as the time from diagnosis of breast cancer to
the first occurrence of metastasis. TTP was measured as the
difference between time of response and time of disease
progression. Thus, patients with no response were not included
for calculation of TTP. OS was measured from inclusion into the
trial to death from any cause, or censored as the date of last
information when death was not recorded before the cutoff date
(1 May 2009).
Measurements of plasma DHA
A mean number of six samples were obtained for each patient
during the time course of the study. Venous blood was collected on
EDTA and centrifuged at 900g for 10min to obtain plasma, which
was divided into five aliquots and immediately stored at  201C. At
the time of analysis, an aliquot of each sample was unfrozen.
Samples were analysed each day in batches of 24, in which patients
were randomly distributed. Each sample was labelled with a code
number that was blinded to the operators (ML and MP).
Plasma lipids were extracted with chloroform/methanol (2:1,
vol/vol) (Folch et al, 1957). Phospholipids were purified with one-
dimensional thin layer chromatography, transmethylated and fatty
acid methyl esters analysed by gas chromatography on an AS 2000
gas chromatograph (ThermoFinnigan, Courtaboeuf Cedex, France)
equipped with a cold on-column injector and a 60m BPX 70
capillary column, with the aid of an automatic injector, under
conditions as described earlier (Chaje `s et al, 1999). Peaks were
identified by comparison of their retention times with those of
authentic lipid standards (Supelco 37 Component FAME Mix,
Sigma-Aldrich, Saint-Quentin Fallavier, France). Reproducibility of
retention times was controlled by adding the standard before and
after each batch. Fatty acid levels were calculated as percentages of
total peak areas using ChromQuest software (ThermoFinnigan).
Fatty acids were expressed as weight percentage (% of total peak
area). Repeatability of the chromatography procedure was estimated
from a sample earlier subdivided into 10 aliquots extracted and
analysed on the same day. The coefficient of variations (CVs) of each
fatty acid peak area was less than 0.5% for major peaks (such as 18:2
o-6c, 18:1 o-9c and 16:0) and not 410% for minor peaks, that is
peaks o1% of total fatty acids.
Statistical considerations
Sample size and termination rules A total of 25 patients were
required to provide a 95% confidence interval (CI) ranging from
0.11 (no response) to 0.41 (12 or 13 responses). After Gehan’s rules
for trial termination, the probability of observing five consecutive
lack of responses was 0.03 for an estimated 50% ORR (Gehan, 1961).
Thus, as a first step, five patients were included. In case of no
objective response, the trial would have been stopped. In the case of
at least one objective response, the trial would be continued.
Statistical methods All patients were included into the analysis.
Data were presented as median and extremes. The Wilcoxon test
was performed to compare the plasma DHA level at the end of the
loading period with baseline. The relationship between patient
DHA incorporation and baseline characteristics or toxicities
observed was analysed using the Mann–Whitney test or Fisher’s
exact test. The Kaplan–Meier method and log-rank test were
applied for survival calculation. Statistical analyses were per-
formed with the GraphPad Prism 4 software (GraphPad Software,
Inc., San Diego, USA). Po 0.05 was regarded as significant.
RESULTS
Patients were enrolled between February 2001 and April 2003 to
receive the DHA/FEC combination. Table 1 presents patients’
characteristics at baseline. The median age was 58 years,
performance status was 0 or 1 in 96% of cases. Most patients (19
out of 25) had received earlier therapy, including adjuvant or
neo-adjuvant anthracycline-based chemotherapy (40%), chest wall
radiation therapy or hormonal therapy (adjuvant or metastatic)
(64%). Twelve patients had received tamoxifene as an adjuvant
hormonal therapy (two patients had been switched to an
aromatase inhibitor). The median duration of this hormonal
treatment was 29 months (range 8–60 months), one patient had
received hormonal therapy for 5 years. Four patients had received
hormonal therapy as first-line treatment for metastases. Disease
extension was severe in most cases, with 72% of liver metastases.
Forty per cent had three or more metastatic sites.
The median DHA level at baseline was 2.6% of total fatty acids
(range 1.6% to 5%). At the end of the loading period, it reached
5.1% (range 2.5% to 8.3%, Po0.0001) (Figure 1A). The DHA level
was 6.0% at cycle 4 (range 2.9% to 9.7%) and 6.4% at cycle 6 (range
3.5% to 8.9%). The extent of DHA increase at the end of the
loading period differed among patients. It ranged from 0% to 4.3%
with a Gaussian distribution (Figure 1B), allowing the definition of
two groups of patients according to their ability to incorporate
DHA: a group with high-DHA (H-DHA) incorporation and a group
with lower-DHA incorporation (L-DHA), the cutoff being the
median value (2.5%). Baseline characteristics of the two groups
Table 1 Patients’ characteristics at baseline
n¼25
n (%)
Median age in years (range) 58 (32–71)
ECOG performance status
a
0 9 (36)
1 15 (60)
2 1 (4)
Number of metastatic location
1 5 (20)
2 10 (40)
X3 10 (40)
Metastatic location
Liver 17 (68)
Lung 9 (36)
Bone 15 (60)
Skin 5 (20)
Brain 1 (4)
Menopausal status
Post-menopaused 21 (84)
Pre-menopaused 4 (16)
Oestrogen receptor status
Positive 17 (68)
Negative 7 (28)
Unknown 1 (4)
Progesterone receptor status
Positive 16 (64)
Negative 7 (28)
Unknown 2 (8)
HER 2 status
Positive 3 (12)
Negative 18 (72)
Unknown 4 (16)
Prior treatments
b 19 (76)
Abbreviation:
aECOG¼Eastern Cooperative Oncology Group.
bChemotherapy,
radiation therapy or hormonal therapy.
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swere balanced: median age was 58 years in the H-DHA group and
57 years in the L-DHA group, 58% of patients had a performance
status of 1 in the H-DHA group vs 62% in the L-DHA group, one
patient had a performance status of 2 in the L-DHA group, 83% of
patients had 2 or more metastatic locations in the H-DHA group vs
77% in the L-DHA group and there was liver involvement in 67%
and 77% of cases, respectively. Oestrogen receptors in primary
tumour were positive in 67% or 69% of patients in the H-DHA or
L-DHA groups, respectively. One patient had a positive HER-2
status in the primary tumour in the H-DHA group vs two patients
in the L-DHA group. The median metastases-free interval was 3
years in both groups (range 0–13 years in the H-DHA group and
0–20 years in the L-DHA group). Five patients had synchronous
metastases at the time of cancer diagnosis in the H-DHA group
and two patients in the L-DHA group (P¼0.2, Fisher’s test). Three
patients received adjuvant hormonal therapy by tamoxifene in the
H-DHA group and nine patients in the L-DHA group (P¼0.05,
Fisher’s test). Tamoxifene was switched to an aromatase inhibitor
in two patients in the L-DHA group (none in the H-DHA group).
The baseline DHA level was 2.6% (range 1.6–4.3%) in the H-DHA
group and 2.7% (range 1.8–5%) in the L-DHA group.
Efficacy
Among the first five patients evaluable for response, we observed
two PRs; therefore, the trial was completed. All patients took the
DHA supplementation as planned, with a global compliance of
90%. A total of 163 cycles of FEC were administered along with
DHA supplementation, with a median number of six cycles per
patient (range 3–9) in H-DHA or L-DHA incorporation groups.
The ORR was 44% (95% CI, 24.5–63.5) (1 CR and 10 PR). There
were 11 SD cases and three PD cases. The clinical benefit achieved
was 88%. With a mean follow-up of 31 months (range 2–96
months), the median TTP was 6 months (95% CI, 2.8–8.7 months)
(Figure 2A). Median OS was 22 months (95% CI, 17–33 months)
(Figure 2C). One patient was still living as of June 2009. TTP
(Figure 2B) was greater in the H-DHA group, with a median TTP of
8.7 months vs 3.5 months in the L-DHA group (P¼0.02). OS
(Figure 2D) was significantly greater in the H-DHA group with a
median survival time of 34 months vs 18 months in the L-DHA
group (P¼0.007). The type of post-trial treatments did not differ
between the two groups. Two patients received no further systemic
treatment (one in each group), 15 patients received an aromatase
inhibitor (6 out of 12 and 9 out of 13 in the H-DHA and L-DHA
groups, respectively, ns) and 7 patients received chemotherapy by
docetaxel (4 out of 12 and 3 out of 13 in the H-DHA and L-DHA
groups, respectively, ns). The median number of lines of post-trial
chemotherapy and anti-cancer drugs used (including a taxane or
trastuzumab) was similar in both groups. Survival analysis by
hormonal status or by adjuvant hormonal therapy (received or
not) showed no influence of these factors on survival (data not
shown).
Safety
All patients were evaluated for safety. DHA supplementation was
well tolerated. No DHA-related adverse events were observed
either during the loading period or FEC chemotherapy. Delay in
the administration of chemotherapy occurred in 15% of cycles and
was lower than 8 days in 84% of cases. Reduction of epirubicin
dose occurred only once (0.6% of cycles). Principal grade 3 or 4
toxicity was neutropaenia (80%), with one case of febrile aplasia.
Anaemia and thrombopaenia occurred in 8% of cases (2 out of 25
patients). Complete alopaecia occurred in 80% of cases. No grade 4
non-haematological adverse events were recorded. Grade 3 toxicity
was infrequent. No grade 3 or 4 cardiac toxicity was reported.
Sonographic measurement of cardiac function identified a non-
symptomatic decrease of the LVEF in three patients (grade 1 in two
cases and grade 2 in one case). According to DHA incorporation,
patients in the H-DHA group experienced anaemia and thrombo-
paenia less frequently (P¼0.01) as compared with those in the
L-DHA group (Table 2). Non-haematological toxicities did not
differ among groups.
Treatment was discontinued as a consequence of completion of
therapy in 21 patients, early disease progression in one patient,
haematological toxicity in one patient and non-symptomatic
decrease in LVEF (to a value of 45%) in one patient. One patient
died 15 days after the administration of the third cycle of
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Figure 1 Differential incorporation of DHA among patients. (A) DHA increase after the loading period (LP). Metastatic breast cancer patients received
1.8g/day of oral DHA at inclusion. DHA plasma phospholipid level was measured at baseline and before initiation of chemotherapy. DHA increase was
significant (Po0.0001, Wilcoxon test). (B) Patient distribution according to the extent of DHA increase. The median of this distribution (2.5%) was used as a
threshold to define two groups of patients with a high- (H-DHA, grey bars) or low- (L-DHA, white bars) DHA increase. Black (m) or open (W) triangles
stand for H-DHA or L-DHA incorporation.
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schemotherapy. This patient was 71 years old and had a sudden
alteration of consciousness leading to rapid death. The precise
cause of death could not be identified, but the occurrence of stroke
was suspected. The evaluation made after two cycles did not
indicate any tumour progression. This serious adverse event was
not considered to be related to treatment.
DISCUSSION
This trial is a logical extension of earlier studies carried out in
rodents and shows that a defined food component, namely DHA,
can turn malignant mammary tumours from resistant to sensitive
to chemo- (Colas et al, 2006) or radiation therapy (Colas et al,
2004). Our data show for the first time that a dietary intervention
targeted on DHA is a feasible approach that has potential to
substantially increase survival in metastatic breast cancer patients
treated with chemotherapy.
When compared with historical data, the ORR observed in our
population was within the range (30% to 60%) of that which has
been reported in frontline FEC 75 chemotherapy for breast cancer
metastasis (FESG, 1991, 2000; Pavesi et al, 1995; Pacini et al, 2000;
Capotorto et al, 2003; Bonneterre et al, 2004). In terms of survival,
frontline FEC 75 chemotherapy in this setting has been found to
induce a median TTP ranging from 6 to 13 months and a median
OS ranging from 18 to 23 months, with one single study reporting
28 months (FESG, 1991, 2000; Pavesi et al, 1995; Pacini et al, 2000;
Capotorto et al, 2003; Bonneterre et al, 2004). Although the median
TTP (6 months) and OS (22 months) in our study were within the
frame of published data, it should be stressed that our patient
population had a particularly poor prognosis, as 68% had liver
metastases in addition to other sites of metastases. The median OS
of patients having liver metastases was reported to be 14 months
(Atalay et al, 2003). Moreover, we observed wide disparities in
survival among patients, ranging from 2.8 to 8.7 months for TTP
and from 17 to 33 months for OS (95% CI).
Orally provided fatty acids must be incorporated in cell
membranes to be effective, and this could be impeded in various
individual cancer patients by a variety of metabolic defects. For
these reasons, this study has been analysed as a function of DHA
incorporation. We observed wide inter-individual disparities in
DHA incorporation in plasma phospholipids at the end of the
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96
0
10
20
30
40
50
60
70
80
90
100
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
0 3 6 9 12 15 18 21 24 27 30
0
10
20
30
40
50
60
70
80
90
100
70 76 82
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
0 3 6 9 12 15 18 21 24 27 30
0
10
20
30
40
50
60
70
80
90
100
70 76 82
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96
0
10
20
30
40
50
60
70
80
90
100
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
High
Low
Time to progression
Overall survival
Global
High
Low
By DHA incorporation
By DHA incorporation
Global
Time (months)
Time (months)
Time (months)
Time (months)
18 months
34 months
3.5 months
8.7 months
P=0.02
P=0.007
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sloading period. Those disparities were unexpected, as global
compliance was 90% of the planned dose. We identified that
survival was associated with the extent of DHA incorporated into
plasma phospholipids. When patients were stratified according to
this factor, TTP was significantly higher in patients with an
H-DHA incorporation (8.7 months vs 3.5 months in patients with
L-DHA incorporation), suggesting a greater efficacy of chemo-
therapy. Most importantly, OS was almost doubled in patients with
H-DHA incorporation (34 months vs 18 months). The significant
difference observed between patients with H-DHA or L-DHA
incorporation could not be ascribed to differences in earlier
hormonal therapy, time to metastases, DHA level at baseline or
post-trial treatments among the two patient groups. Although the
design of the study does not allow for confirmation that DHA
increased the basal activity of chemotherapy, the fact that both
TTP and OS were vastly different according to the level of DHA
incorporated indicates that the addition of DHA to chemotherapy
had a beneficial effect when highly incorporated. This assumption
was strengthened by the fact that no factor other than DHA
incorporation could account for the difference in survival
observed. In particular, the level of any contaminants with
endocrine disruptor activity in DHASCO capsules was too low
(under the pg/day) to account for a bias in this population of
patients consisting of 68% ER positives.
DHA is a ubiquitous structural component of cell membranes.
DHA is mainly provided by diet, as its rate of endogenous
synthesis through elongation and desaturation steps from
a-linolenic acid is limited (Burdge, 2006). In tumour tissues,
DHA is thought to originate from diet, because a positive
correlation between the DHA content of tumour and non-tumour
epithelial breast tissues has been observed, and because the fatty
acid desaturation activity in human breast tumour tissues has been
found to be very low or absent (Chajes et al, 1995). After
absorption, DHA incorporates into plasma phospholipids, which is
a route for the delivery of DHA to tissues (Lagarde et al, 2001;
Polozova et al, 2006). This includes tumours, as indicated by the
concomitant increase in the DHA content of plasma phospholipids
and tumours in cancer patients reported by Senkal et al (2005).
Thus, besides its relevance as a biomarker of DHA intake, plasma
phospholipid DHA content may also reflect the availability of DHA
to tissues, including tumours. Therefore, the disparities in DHA
incorporation into plasma phospholipids could be an indicator of
a differential incorporation of DHA into metastatic tumour tissue
among patients, which is higher in patients with a marked plasma
DHA increase. Our results indicate that DHA incorporation is a
relevant factor involved in chemotherapy efficacy. Therefore,
during dietary interventions with DHA, appropriate conditions
leading to a consistently elevated plasma DHA content in all
patients have to be investigated. In hypotheses, the concomitance
of DHA intake to food intake may influence DHA incorporation
and has to be taken into account.
Interestingly, and compared with literature, we did not observe
additional toxicity in normal tissues, including in patients with an
H-DHA incorporation. Although DHA is a non-toxic compound
(Kroes et al, 2003), its incorporation into blood cell precursors
(Vidgren et al, 1997) theoretically could have resulted in an
increased myelosuppression during its prolonged association (16
to 22 weeks) with FEC chemotherapy. However, no increased
haematological toxicity was found as compared with historical
data. It is worth stressing that the reported rates of haematological
toxicity rely heavily on the frequency of blood count assessment.
They could range from 7% to 84% for neutropaenia, 1% to 21% for
anaemia or from 1% to 9% for thrombocytopaenia (Stewart et al,
1997; Blajman et al, 1999; FESG, 2000; Pacini et al, 2000;
Bonneterre et al, 2004; Zielinski et al, 2005). A slightly lower
toxicity of chemotherapy with respect to anaemia and thrombo-
paenia was even observed in the H-DHA group. This is in line with
the protective effects of DHA against the gastrointestinal toxicity
of chemotherapy or radiation therapy in experimental models
(Hardman et al, 1999; Kato et al, 2002; Wen et al, 2003; Xue et al,
2007) or in patients (Minami et al, 2008).
As anthracycline-related myocardial toxicity has been consi-
dered as a consequence of direct myocardial injury by ROS
generated by chemotherapy (Singal et al, 2000; Minotti et al, 2004),
the addition of DHA could have potentially amplified this toxicity.
However, no severe cardiac toxicity was reported in this trial. The
lack of additional cardiac toxicity may result from an efficient ROS
detoxification system by cardiomyocytes, although the possibility
that ROS generation might not be the main determinant in
anthracycline-related heart damage has already been considered in
several studies (Olson et al, 1988; Minotti et al, 2004). Patients with
an H-DHA incorporation did not show increased toxicities to FEC
chemotherapy as compared with patients with an L-DHA
incorporation. Taken together, our results suggest that DHA had
Table 2 Safety of the addition of DHA to FEC chemotherapy according to DHA incorporation
High-DHA incorporation (n¼12) Low-DHA incorporation (n¼13)
Grades 1–2 Grades 3–4 Grades 1–2 Grades 3–4
Toxicity
a n (%) n (%) n (%) n (%) P
0
Neutropaenia 4 (33) 8 (66) 1 (7) 12 (92) 0.1
Febrile neutropaenia 0 0 0 1 (7) ns
Anaemia 5 (41) 1 (8) 12 (92) 1 (7) 0.01
Thrombopaenia 1 (8) 1 (8) 8 (62) 1 (7) 0.02
Performance status 9 (75) 0 10 (77) 0 ns
Asthenia 9 (75) 0 10 (77) 0 ns
Alopecia
b 2 (16) 9 (75) 2 (15) 11 (85) ns
Nausea 7 (58) 2 (16) 7 (54) 1 (7) ns
Vomiting 5 (41) 1 (8) 7 (54) 0 ns
Stomatitis 3 (25) 0 2 (15) 1 (7) ns
Pulmonary toxicity 1 (8) 0 2 (15) 0 ns
Transaminases 1 (8) 1 (8) 1 (7) 0 ns
Bilirubin 0 0 0 1 (7) ns
Sensory neuropathy 1 (8) 0 2 (15) 0 ns
Thrombosis 1 (8) 0 1 (8) 0 ns
Cardiac toxicity 2 (16) 0 1 (7) 0 ns
Abbreviations: DHA¼docosahexaenoic acid; ns¼non-significant.
aToxicity was graded using the National Cancer Institute Common Toxicity Criteria.
bGrade 1 alopecia is
indicated in grades 1–2 and grade 2 alopecia in grades 3–4 column.
oFisher’s exact test.
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tissues, and, therefore, acted as a tumour-specific chemosensitiser.
We are currently investigating potential mechanisms in vitro that
may account for a differential effect of DHA on tissues. Recent data
suggest that the anti-oxidant system of tumour cells may be altered
during cancer progression, making tumour cells more sensitive to
ROS damage (Mahe ´o et al, 2005; Vibet et al, 2008; Sun et al, 2009).
Our study has a number of strengths. It involves a homogeneous
population of patients, all receiving identical treatment in one
single cancer centre and being evaluated by one single medical
team within a short period of inclusion. Although the number of
patients involved in the study was small, survival as an end point
and the length of follow-up give strength to the conclusion, as time
to death was not censored in 96% of the patients. This study also
has several limitations. It does not allow for a definitive assessment
of the efficacy of DHA combination to chemotherapy. The design
was not dedicated to comparing two sub-populations according to
their level of plasma DHA. However, the difference in the
likelihood of survival between the two populations suggests that
DHA has a potential to increase the activity of chemotherapy,
and that this potential may be proportional to its degree of
incorporation. We are fully aware that the association reported
between DHA incorporation into plasma phospholipids and
metastatic cancer outcome subsequent to chemotherapy does not
ensure a causality relationship. These results warrant confirmation
through a larger placebo-controlled randomised phase III clinical
trial stratified on patients’ DHA incorporation.
In conclusion, this study shows that addition of DHA to
chemotherapy is devoid of adverse side effects and might improve
the outcome of metastatic breast cancer patients. These results
suggest that DHA has a potential to specifically chemosensitise
tumours. This study represents the incentive to set up a
prospective-controlled randomised trial aimed at identifying the
place of dietary DHA in breast cancer treatments.
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